By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
UB professor shares his experience on almost becoming an astronaut - 2Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 3Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- 4Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- 5Meet the Stars of the Feline World: Well known Pet Feline Varieties
- People are getting their news from AI – and it’s altering their views
- China's Normal Ponders: A Visual Excursion
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- Scientists document a death from a meat allergy tied to certain ticks
- Language Learning Stages: Which One Gets Your Vote?
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
